Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program ...

智通财经APP获悉，11月13日，阿斯利康 (AZN.US)和第一三共宣布，根据美国FDA的反馈，两家公司已为其联合开发的Trop2靶向抗体偶联药物 (ADC)datopotamab deruxtecan (Dato-DXd)递交生物制品许可申请 (BLA)，寻求该疗法获加速批准，用以治疗携带表皮生长因子受体 (EGFR)突变肿瘤的局部晚期或转移性非小细胞肺癌 ...

BioNTech and Biotheus presented data on the drug at the European cancer meeting ESMO in September, hinting at its potential ...

Researchers demonstrate AI-enhanced MRI's potential in diagnosing endometrial cancer, achieving superior accuracy and ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

The initial data we presented at ESMO GI in 2024, just a few months ago from the Cornell study highlights this potential. These results in a tumor type historically resistant to immunotherapy, are ...